RecruitingPhase 2NCT05334316

Individualizing Corticosteroid Use in Pneumonia


Sponsor

Mayo Clinic

Enrollment

24 participants

Start Date

Nov 6, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

In this study, researchers propose a unique (individualized) approach to steroid treatment seeking to give the right dose of steroid to the right patient and at the right time. This study seeks to compare usual care to an individualized steroid dosing strategy by testing a marker of inflammation in the blood called C- reactive protein (CRP). The overall goal is to reduce an individual's exposure to steroids and the risk of potential side effects thereby increasing the potential benefit of using steroids to control inflammation in pneumonia.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Hospitalized adult (≥ 18 years) patients.
  • Community acquired pneumonia.

Exclusion Criteria5

  • Contraindications or unwillingness to use corticosteroids by patient or provider.
  • History of adrenal insufficiency, septic shock, or another absolute indication for steroid use.
  • Suspected pulmonary vasculitis or other autoimmune pulmonary disorder.
  • Positive pregnancy test
  • Comfort care.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDexamethasone

Administered intravenously or orally based on daily CRP values and CRP corticosteroid dosing algorithm


Locations(1)

Mayo Clinic Rochester

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05334316


Related Trials